iQ&A for NTM/MAC Lung Disease

Program Medium
Internet-based program

Method of Physician Participation Utilized in Learning Process

There are no fees for participating and receiving CME credit for this activity. During the period August 1, 2019 through August 6, 2021, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view all 89 segments, totaling 4.5 hours, to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out CME certificate.

Estimated Time to Complete Educational Activity

4.5 hours. Physicians must study the enduring activity, and are expected to view every segment to successfully complete the activity and earn CME credit.

Course Overview

In this web-based program, physicians will learn how recent developments in basic and clinical research have helped to advance the understanding and management of non-tubercular mycobacterial (NTM) pulmonary infection with mycobacterium avium complex (MAC)

Release Date

August 1, 2019

Expiration Date

August 1, 2021

Intended Audience

This complimentary CME educational activity is designed for all healthcare providers (HCPs) involved in developing, delivering, consulting, and monitoring care for patients with non-tubercular mycobacterial (NTM) pulmonary infection with mycobacterium avium complex (MAC), including infectious disease specialists, pulmonary medicine specialists, and related clinicians.


Participation in this iQ &A interactive Medical Intelligence Zone is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support

This activity is supported by an independent medical education grant from Insmed.

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Postgraduate Institute for Medicine and CMEducation Resources, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The University of Massachusetts Medical School, Office of Continuing Medical Education designates this enduring material for a maximum of 4.5 AMA PRA Category 1 Credits(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Policy on Faculty & Provider Disclosure

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Program Faculty and Disclosure

Program Faculty and Disclosure
Antonino Catanzaro, MD

Professor of Medicine Director, Tuberculosis Control
Division of Pulmonary, Critical Care, and Sleep Medicine
UC San Diego School of Medicine
San Diego, California

Nothing to disclose

Patrick A Flume, MD
Professor of Medicine and Pediatrics
Medical University of South Carolina
Powers-Huggins Endowed Chair for Cystic Fibrosis
University of South Carolina
Charleston, South Carolina

Grant Support: Bayer Healthcare AG, Corbus Pharmaceuticals, Cystic Fibrosis Foundation Therapeutics, Galapagos, Insmed, National Institutes of Health, Novartis, Novoteris, Proteostasis Therapeutics, Sound Pharmaceuticals, Vertex Pharmaceuticals Consultantt: Bayer Healthcare AG, Corbus Pharmaceuticals, Eloxx Pharmaceuticals, Horizon Pharma, Insmed, Ionis Pharmaceuticals, McKessoh, Novartis, Proteostasis Therapeutics, Vertex Pharmaceuticals

Shannon Kasperbauer, MD
Associate Professor of Medicine
Department of Medicine
Division of Mycobacterial & Respiratory Infections
National Jewish
Denver, Colorado

Consultant: Johnson & Johnson

Mehdi Mirsaeidi, MD, MPH
Director of University of Miami and VA Sarcoidosis Programs
Co-Director UM NTM Program
IRB Vice-Chairman, Miami VA Healthcare System
Assistant Professor of Department of Medicine
Assistant Professor of Clinical Public Health Sciences
Division of Pulmonary, Critical Care,
Sleep and Allergy
University of Miami, Miller School of Medicine
Miami, Florida

Nothing to disclose

Julie V. Philley, MD
Chair of the Department of Medicine
Chief of Pulmonary and Critical Care
UT Health North Campus Tyler
The University of Texas Health Sciences Center
Houston, Texas

Consultant and Advisory Board: Insmed

Stephen Ruoss, MD
Professor of Medicine Clinical Chief, Pulmonary and Critical Care Medicine Division
Department of Medicine
Medical Director, Stanford Medical Center Respiratory Care Services, Stanford Medical Center
Medical Director, Stanford Medical Center Transfer Center,
Stanford University Medical Center
Stanford, California

Advisory Board: Insmed

Program Managers and Web Editor Disclosure

Program Manager Gideon Bosker, MD has nothing to disclose.

Educational Objectives

Upon completion of this activity, participants will be able to:

  • Understand and discuss the epidemiology and disease burden for NTM-PD based on regional prevalence, susceptible populations, and strategies for confirming the diagnosis of NTM-PD
  • Outline the burden of NTM-PD for patients and the healthcare system, especially in regions with high disease burden and poor recognition of this challenging condition
  • Compare and differentiate the mechanism of action and delivery systems of different antimicrobial formulations and how these MOA will affect microbial conversion and eradication in NTM-PD
  • Detail the risk factors for and clinical presentation of NTM-PD, and initial guideline-based therapy (GBT)
  • Evaluate and deploy national (ACCP, ATS, BTS, and IDSA) guideline-based treatment (GBT) and recommendations for the diagnosis, assessment, and treatment of NTM, especially refractory, non-converting NTM-PD

Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to print out the CME certificate.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

  • We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
  • For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
  • We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
  • If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
  • You should check this privacy policy periodically to see whether we have made any changes.


Copyright © 2019 by CMEducation Resources, LLC All rights reserved. 

Reproduction, distribution, or translation without express written permission is strictly prohibited. 

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity. 

Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations. 

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman. 

Opinions expressed herein are not necessarily those of Pharmatecture, LLC, CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.